check out medication prices at rxbyfax valid prescription mandatory Canadian online pharmacy

Many of us have heard much about bromelain. Bromelain is found in pineapple and other tropical fruit. Bromelain is a mini pharmacy. People use bromelain to help digestion and indigestion, to help prevent blood clots from forming, for back aches,bronchitis, for burn debridement, osteoarthritis, and sinus discomfort because of its anti inflammatory properties and possibly for inflammatory bowel disease (IBD) and MS. . Bromelain may increase the potency of antibiotics and chemotherapy. Yes..more resesearch should be done. It can't be patented so the research will continue to be slow. Papaya and pineapple are the main source of proteolytic (protein dissolving) plant enzymes. Bromelain also contains perioxidase, acid phosphatase, protease inhibitors and calcium. I am including research abstracts which contain a lot of phrases you probably don't know..that is all right..I usually just skim them and look for key phrases that validate or at least strongly suggest some of the claims we read about and feel more comfortable about using bromelain for my animals and me....don't worry if a lot of these abstracts for the most part are meant for researchers...Oh yes, bromelain is being used in some cat's supplements to help prevent hairballs.Phlogenzym is a mix of three enzymes: bromelain, which comes from the stem of the pineapple plant; rutin, derived from citrus fruits; and trypsin, which is usually taken from hog pancreases.
I just adopted a kitty cat with sinus problems. I plan to buy empty gel capsules to make a smaller dosage and buy bromelain for her sinus problems to see if that will help her sneezing bouts which helps clear her nose besides her sinus. Have also read it helps with salviation problems.
PETsMART.com Specials
"Cat Lube Hairball & Digestive Aid by Veterinarian's Best Most over the counter hairball remedies contain petroleum, but Cat Lube Hairball and Digestive Aid uses herbs and enzymes to naturally lubricate the digestive tract. Chewable tablets can be fed as a treat, crumbled on dry food or mixed with wet food; suggested usage is one tablet twice daily. Active ingredients: extract of Slippery elm bark and papaya extract."


Clin Immunol. 2005 Jun 1; [Epub ahead of print] : Treatment with oral bromelain decreases colonic inflammation in the IL-10-deficient murine model of inflammatory bowel disease.
Hale LP, Greer PK, Trinh CT, Gottfried MR.
Department of Pathology, DUMC 3712, Duke University Medical Center, Durham, NC 27710, USA.

Bromelain is a mixture of proteinases derived from pineapple stem that is marketed in health food stores as a "digestive aid". Orally administered bromelain was anecdotally reported to induce clinical and endoscopic remission of ulcerative colitis in two patients whose disease was refractory to multi-agent conventional medical therapy. However, the potential efficacy of bromelain in colitis has not yet been tested rigorously in either animals or humans. In this study, the clinical and histologic severity of inflammatory bowel disease (IBD) was determined in IL-10(-/-) mice treated orally with bromelain in vivo. Daily treatment with oral bromelain beginning at age 5 weeks decreased the incidence and severity of spontaneous colitis in C57BL/6 IL-10(-/-) mice. Bromelain also significantly decreased the clinical and histologic severity of colonic inflammation when administered to piroxicam-exposed IL-10(-/-) mice with established colitis. Proteolytically active bromelain was required for anti-inflammatory effects in vivo. Adverse effects of dermatitis, hair loss, and weight loss due to mucositis were rare, dose related, and were not seen in wild-type mice treated orally with up to 1000 mg bromelain/kg/day for 18 weeks. Although the exact mechanisms by which exogenous proteinases affect bowel inflammation have not yet been determined, the results justify additional studies of this complementary biologically based approach to treatment of IBD.
: Mult Scler. 2005 Apr;11(2):166-8. : A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis.
Baumhackl U, Kappos L, Radue EW, Freitag P, Guseo A, Daumer M, Mertin J.
Department of Neurology, Central Clinic, St Poelten, Austria.
neurologie@kh-st-poelten.at

Oral administration of hydrolytic enzymes (HE), such as bromelain, trypsin and rutosid, may have beneficial effects on the clinical course of neurological symptoms related to multiple sclerosis (MS). This is supported by a complete protection by HE from experimental allergic encephalomyelitis, an animal model related to MS. Three hundred and one patients with relapsing MS were enrolled in a double-blind, placebo-controlled trial. No treatment effect between the placebo and the HE groups was found either for clinical or MRI parameters.In Vivo. 2005 Mar-Apr;19(2):417-21. : Therapeutic use, efficiency and safety of the proteolytic pineapple enzyme Bromelain-POS in children with acute sinusitis in Germany.
Braun JM, Schneider B, Beuth HJ.
Institute of Immunology and Transfusion Medicine (IKIT), Interdisciplinary Centre of Clinical Research (IZKF), University of Leipzig, Johannisallee 30, 04103 Leipzig, Germany.
Josef.Beuth@medizin.uni-Koeln.de
The therapeutic efficiency and safety of the proteolytic enzyme bromelaine obtained from pineapple (Bromelain-POS, Ursapharm GmbH, Saarbrucken, Germany) was evaluated in children under the age of 11 years diagnosed with acute sinusitis. Data from 116 patients from 19 centres located across Germany were analysed in a pharmacoepidemiological cohort study. Patient cohorts were either treated with Bromelain-POS (N = 62), in combination with Bromelain-POS and standard therapies (N = 34), or with standard therapies (N = 20). The primary parameter measuring effectiveness of the different treatment groups was the duration of symptoms. The shortest mean period of symptoms was observed in patients treated with Bromelain-POS alone (6.66 days), followed by the standard therapy (7.95 days) and those treated with a combination of Bromelain-POS and the standard therapy (9.06 days). Patients of the Bromelain-POS monotherapy group showed a statistically significant faster recovery from symptoms (p = 0.005) compared to the other treatment groups. One 10-year-old male patient, with a known pineapple allergy, showed a self-limiting mild allergic reaction. No other unwanted side-effects were reported. This trial documents that the proteolytic pineapple enzyme Bromelain-POS is widely used in the treatment of young children diagnosed with acute sinusitis in Germany and that the use of proteolytic enzymes can benefit such patients.
Burns. 2004 Dec;30(8):843-50. : Safety and efficacy of a proteolytic enzyme for enzymatic burn debridement: a preliminary report.
Rosenberg L, Lapid O, Bogdanov-Berezovsky A, Glesinger R, Krieger Y, Silberstein E, Sagi A, Judkins K, Singer AJ.
Department of Plastic and Reconstructive Surgery, and the Burn Unit, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, POB 151, Beer-Sheva 84101, Israel.
proflior@netvision.net.il
A prospective, non-comparative study design was used to describe our experience with a bromelain-derived debriding agent, Debridase, in 130 patients with 332 deep second degree and third degree burns treated between 1984 and 1999. Debridase was applied after saturating the burns with a moist dressing for 2-24h. Debridase was applied for a period of 4h under an occlusive dressing. Mean patient age was 18.6 +/- 19.3, 42 (32.3%) were female, and 63 (48.5%) were children under age 18. Most burns were small. Debridase was applied once in 241 (72.6%) of the 332 wounds, twice in 67 (20.18%) cases, three times in 12 (3.61%) cases, and four times in 2 (0.6%) cases. The percentage debridement by number of applications was 89 +/- 21% for a single application, 77 +/- 27% for two, and 62 +/- 27% for three Debridase applications, respectively. There were no significant adverse events. The availability of a fast acting, reliable and complication-free enzymatic debriding agent may open new horizons and provide a new treatment modality for burns.
Evid Based Complement Alternat Med. 2004 Dec;1(3):251-257. Epub 2004 Oct 6. : Bromelain as a Treatment for Osteoarthritis: a Review of Clinical Studies.
Brien S, Lewith G, Walker A, Hicks SM, Middleton D.

Bromelain, an extract from the pineapple plant, has been demonstrated to show anti-inflammatory and analgesic properties and may provide a safer alternative or adjunctive treatment for osteoarthritis. All previous trials, which have been uncontrolled or comparative studies, indicate its potential use for the treatment of osteoarthritis. This paper reviews the mechanism of its putative therapeutic actions, those clinical trials that have assessed its use in osteoarthritis to date, as well as considering the safety implications of this supplement for osteoarthritis and reviewing the evidence to date regarding the dosage for treating this condition. The data available at present indicate the need for trials to establish the efficacy and optimum dosage for bromelain and the need for adequate prospective adverse event monitoring in such chronic conditions as osteoarthritis
J Assoc Physicians India. 2001 Jun;49:617-21. : Efficacy and tolerability of oral enzyme therapy as compared to diclofenac in active osteoarthrosis of knee joint: an open randomized controlled clinical trial.
Tilwe GH, Beria S, Turakhia NH, Daftary GV, Schiess W.
Department of Medicine, GS Medical College and KEM Hospital, Mumbai.

OBJECTIVE: To compare the efficacy and tolerability of an oral enzyme preparation (Phlogenzym) with that of an NSAID (diclofenac) in the treatment of active osteoarthrosis. METHODS: Prospective, randomized, controlled, single-blind study of seven weeks duration at a tertiary care centre wherein 50 patients aged 40-75 years, with activated osteoarthrosis of knee joint were randomized to receive phlogenzym tablets (2-3 tablets, bid) or diclofenac sodium 50 mg bid for three weeks. RESULTS: At the end of therapy (three weeks) and at follow-up visit at seven weeks there was reduction in pain and joint tenderness and swelling in both groups, and slight improvement in the range of movement in the study group. The reduction in joint tenderness was greater (p < 0.05) in the study group receiving phlogenzym. CONCLUSION: Phlogenzym is as efficacious and well tolerated as diclofenac sodium in the management of active osteoarthrosis over three weeks of treatment.
Research